Alvotech (ALVO) News
Track canonical SquawkNews coverage tagged to ALVO, Alvotech. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 14 indexed stories across 8 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Alvotech jumps after Barclays upgrade and doubled FDA optimism
Alvotech (ALVO) rose about 8% intraday in U.S. trading after Barclays flipped its rating and doubled its price target, saying it is optimistic about FDA approving three biosimilar programs.
EQUITY | Sep 16, 2026, 06:33 PM UTC
H
LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Nasdaq Composite gaining around 150 points on Wednesday. Shares of LuxExperience BV-ADR (NYSE: LUXE ) rose sharply after the company reported fourth-quarter results. LuxExperience reporte
LIVE | Sep 16, 2026, 01:57 PM UTC
M
Barclays raises Alvotech price target to $8
EQUITY | Sep 16, 2026, 12:57 PM UTC
H
ALVO: Pending FDA approvals and strong biosimilar launches drive growth, with robust financial outlook
Multiple BLAs are pending FDA approval, with positive inspection outcomes and launches expected by year-end. Direct U.S. commercialization is expanding for select products, while European biosimilar launches show strong
REGULATION | Sep 15, 2026, 05:22 PM UTC
M
Alvotech shares rise after FDA accepts review for Crohn’s drug
Alvotech shares rose after the FDA accepted AVT80 for review for a Crohn’s treatment.
REGULATION | Aug 31, 2026, 04:56 PM UTC
L
Alvotech to present at upcoming investor conferences in September
Alvotech to present at upcoming investor conferences in September
EQUITY | Aug 27, 2026, 12:07 PM UTC
L
BofA Merrill Lynch initiates ALVO at Buy, $7 target
BofA Merrill Lynch initiates coverage of ALVO with a Buy rating and a $7 price target.
EQUITY | Aug 24, 2026, 12:42 PM UTC
L
BofA Securities initiates ALVO at Buy, $7.00 target
BofA Securities initiates coverage of ALVO with a Buy rating and a $7.00 price target.
EQUITY | Aug 24, 2026, 11:59 AM UTC
L
Alvotech reaffirms 2026 revenue and adjusted EBITDA guidance
Alvotech said first-half 2026 revenue was $212 million, down from $306 million in 2025, and reaffirmed 2026 guidance of $650 million to $700 million revenue and $180 million to $220 million adjusted EBITDA.
EARNINGS | Aug 20, 2026, 01:13 PM UTC
L
Alvotech affirms FY2026 sales guidance at $650 million-$700 million
Alvotech affirms FY2026 sales outlook at $650.000 million-$700.000 million, unchanged from the prior range and above the $644.838 million estimate.
EARNINGS | Aug 19, 2026, 08:30 PM UTC
L
Alvotech reports first-half 2026 financial results, issues business update
Alvotech announces financial results for the first half of 2026 and provides a business update.
EARNINGS | Aug 19, 2026, 08:30 PM UTC
L
WOLF, ALVO, COTY, BABA flagged for earnings tonight and tomorrow
WOLF, ALVO, COTY and BABA are listed in a MarketTalk note as EPS reporters tonight and tomorrow morning, with the note flagging serial-disappointer risk but supplying no company-specific catalyst or figures.
EARNINGS | Aug 19, 2026, 06:13 PM UTC
H
After-market earnings due Wednesday for 11 companies
TradeXchange Newsdesk lists after-market earnings for Wednesday Aug. 19 for ALVO, ARAY, BILL, BULL, CLIR, COTY, IOND, JBSS, NDSN, UFI and WOLF.
EARNINGS | Aug 19, 2026, 02:42 PM UTC
L
Alvotech Strengthens Liquidity With $75M Term Loan, Building On Recent $165M Equity Raise For Total $240M In New Capital
$75 million additional term loan facility maturing December 31, 2027, led by GoldenTree Asset Management — Follows recent $165m equity raise strengthening cash position — Including equity financing and undrawn loan facil
EQUITY | Jul 01, 2026, 08:05 AM UTC